Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML

de Botton, S., Fenaux, P., Yee, K., Récher, C., Wei, A. H., Montesinos, P., Taussig, D. C., Pigneux, A., Braun, T., Curti, A., Grove, C., Jonas, B. A., Khwaja, A., Legrand, O., Peterlin, P., Arnan, M., Blum, W., Cilloni, D., Hiwase, D. K., … Cortes, J. (2023). Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. Blood Advances, 7(13), 3117–3127. https://doi.org/10.1182/bloodadvances.2022009411
Authors:
Stéphane de Botton
Pierre Fenaux
Karen Yee
Christian Récher
Andrew H Wei
Pau Montesinos
David C Taussig
Arnaud Pigneux
Thorsten Braun
Antonio Curti
Carolyn Grove
Brian A Jonas
Asim Khwaja
Ollivier Legrand
Pierre Peterlin
Montserrat Arnan
William Blum
Daniela Cilloni
Devendra K Hiwase
Joseph G Jurcic
Jürgen Krauter
Xavier Thomas
Justin M Watts
Jay Yang
Olga Polyanskaya
Julie Brevard
Jennifer Sweeney
Emma Barrett
Jorge Cortes
Affiliated Authors:
Joseph G Jurcic
Columbia Affiliation:
Subjects:
Quinolines (MeSH)
Leukemia, Myeloid, Acute (MeSH)
elink
Publication Type:
Article
Unique ID:
10.1182/bloodadvances.2022009411
PMID:
36724515
DOI:
10.1182/bloodadvances.2022009411
Journal:
Blood Advances
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Scopus Record

Record Created: